Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortizatization of Intangibles: 2016-2023

Historic Amortizatization of Intangibles for Seres Therapeutics (MCRB) over the last 5 years, with Jun 2023 value amounting to $49,000.

  • Seres Therapeutics' Amortizatization of Intangibles rose 120.94% to $49,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $95,000, marking a year-over-year decrease of 82.28%. This contributed to the annual value of $236,000 for FY2023, which is 134.30% up from last year.
  • Seres Therapeutics' Amortizatization of Intangibles amounted to $49,000 in Q2 2023, which was down 73.80% from $187,000 recorded in Q1 2023.
  • Seres Therapeutics' Amortizatization of Intangibles' 5-year high stood at $1.6 million during Q4 2021, with a 5-year trough of -$851,000 in Q1 2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was -$181,500 (2022), whereas its average is -$95,000.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first spiked by 466.67% in 2019, then tumbled by 17,300.00% in 2021.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Amortizatization of Intangibles stood at $85,000 in 2019, then plummeted by 748.24% to -$551,000 in 2020, then surged by 390.20% to $1.6 million in 2021, then crashed by 100.75% to -$12,000 in 2022, then skyrocketed by 120.94% to $49,000 in 2023.
  • Its last three reported values are $49,000 in Q2 2023, $187,000 for Q1 2023, and -$12,000 during Q4 2022.